138 related articles for article (PubMed ID: 32239164)
1. A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048.
McCarthy JS; Donini C; Chalon S; Woodford J; Marquart L; Collins KA; Rozenberg FD; Fidock DA; Cherkaoui-Rbati MH; Gobeau N; Möhrle JJ
Clin Infect Dis; 2020 Dec; 71(10):e657-e664. PubMed ID: 32239164
[TBL] [Abstract][Full Text] [Related]
2. Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel
Sinxadi P; Donini C; Johnstone H; Langdon G; Wiesner L; Allen E; Duparc S; Chalon S; McCarthy JS; Lorch U; Chibale K; Möhrle J; Barnes KI
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932368
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
[TBL] [Abstract][Full Text] [Related]
5. Antimalarial efficacy of MMV390048, an inhibitor of
Paquet T; Le Manach C; Cabrera DG; Younis Y; Henrich PP; Abraham TS; Lee MCS; Basak R; Ghidelli-Disse S; Lafuente-Monasterio MJ; Bantscheff M; Ruecker A; Blagborough AM; Zakutansky SE; Zeeman AM; White KL; Shackleford DM; Mannila J; Morizzi J; Scheurer C; Angulo-Barturen I; Martínez MS; Ferrer S; Sanz LM; Gamo FJ; Reader J; Botha M; Dechering KJ; Sauerwein RW; Tungtaeng A; Vanachayangkul P; Lim CS; Burrows J; Witty MJ; Marsh KC; Bodenreider C; Rochford R; Solapure SM; Jiménez-Díaz MB; Wittlin S; Charman SA; Donini C; Campo B; Birkholtz LM; Hanson KK; Drewes G; Kocken CHM; Delves MJ; Leroy D; Fidock DA; Waterson D; Street LJ; Chibale K
Sci Transl Med; 2017 Apr; 9(387):. PubMed ID: 28446690
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria.
Mohammed R; Asres MS; Gudina EK; Adissu W; Johnstone H; Marrast AC; Donini C; Duparc S; Yilma D
Am J Trop Med Hyg; 2023 Jan; 108(1):81-84. PubMed ID: 36509063
[TBL] [Abstract][Full Text] [Related]
8. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study.
McCarthy JS; Lotharius J; Rückle T; Chalon S; Phillips MA; Elliott S; Sekuloski S; Griffin P; Ng CL; Fidock DA; Marquart L; Williams NS; Gobeau N; Bebrevska L; Rosario M; Marsh K; Möhrle JJ
Lancet Infect Dis; 2017 Jun; 17(6):626-635. PubMed ID: 28363636
[TBL] [Abstract][Full Text] [Related]
9. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial.
Phyo AP; Jittamala P; Nosten FH; Pukrittayakamee S; Imwong M; White NJ; Duparc S; Macintyre F; Baker M; Möhrle JJ
Lancet Infect Dis; 2016 Jan; 16(1):61-69. PubMed ID: 26448141
[TBL] [Abstract][Full Text] [Related]
10. Characterising the blood-stage antimalarial activity of pyronaridine in healthy volunteers experimentally infected with Plasmodium falciparum.
Barber BE; Webster R; Potter AJ; Llewellyn S; Sahai N; Leelasena I; Mathison S; Kuritz K; Flynn J; Chalon S; Marrast AC; Gobeau N; Moehrle JJ
Int J Antimicrob Agents; 2024 Jul; 64(1):107196. PubMed ID: 38734217
[TBL] [Abstract][Full Text] [Related]
11. Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria.
Wattanakul T; Baker M; Mohrle J; McWhinney B; Hoglund RM; McCarthy JS; Tarning J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468477
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of the Antimalarial MMV390048 against
Ji S; Galon EM; Rizk MA; Yi Y; Zafar I; Li H; Ma Z; Iguchi A; Asada M; Liu M; Xuan X
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0057422. PubMed ID: 35924942
[TBL] [Abstract][Full Text] [Related]
13. Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
Watts RE; Odedra A; Marquart L; Webb L; Abd-Rahman AN; Cascales L; Chalon S; Rebelo M; Pava Z; Collins KA; Pasay C; Chen N; Peatey CL; Möhrle JJ; McCarthy JS
PLoS Med; 2020 Aug; 17(8):e1003203. PubMed ID: 32822347
[TBL] [Abstract][Full Text] [Related]
14. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
[TBL] [Abstract][Full Text] [Related]
15. A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers.
McCarthy JS; Rückle T; Elliott SL; Ballard E; Collins KA; Marquart L; Griffin P; Chalon S; Möhrle JJ
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31685476
[TBL] [Abstract][Full Text] [Related]
16. Chemoprotective Antimalarial Activity of P218 against Plasmodium falciparum: A Randomized, Placebo-Controlled Volunteer Infection Study.
Chughlay MF; El Gaaloul M; Donini C; Campo B; Berghmans PJ; Lucardie A; Marx MW; Cherkaoui-Rbati MH; Langdon G; Angulo-Barturen I; Viera S; Rosanas-Urgell A; Van Geertruyden JP; Chalon S
Am J Trop Med Hyg; 2021 Feb; 104(4):1348-1358. PubMed ID: 33556040
[TBL] [Abstract][Full Text] [Related]
17. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia.
Yang H; Wang J; Liu H; Li X; Nie R; Li C; Wang H; Wang Q; Cao Y; Cui L
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987144
[TBL] [Abstract][Full Text] [Related]
19. A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study.
McCarthy JS; Rückle T; Djeriou E; Cantalloube C; Ter-Minassian D; Baker M; O'Rourke P; Griffin P; Marquart L; Hooft van Huijsduijnen R; Möhrle JJ
Malar J; 2016 Sep; 15(1):469. PubMed ID: 27624471
[TBL] [Abstract][Full Text] [Related]
20. A randomized feasibility trial comparing four antimalarial drug regimens to induce
Reuling IJ; van de Schans LA; Coffeng LE; Lanke K; Meerstein-Kessel L; Graumans W; van Gemert GJ; Teelen K; Siebelink-Stoter R; van de Vegte-Bolmer M; de Mast Q; van der Ven AJ; Ivinson K; Hermsen CC; de Vlas S; Bradley J; Collins KA; Ockenhouse CF; McCarthy J; Sauerwein RW; Bousema T
Elife; 2018 Feb; 7():. PubMed ID: 29482720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
